Cart
sales@molnova.com
m-PEG11-Br
CAS No. 1258596-39-2
m-PEG11-Br( —— )
Catalog No. M23430 CAS No. 1258596-39-2
m-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 100MG | 91 | In Stock |
|
| 200MG | 137 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namem-PEG11-Br
-
NoteResearch use only, not for human use.
-
Brief Descriptionm-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Descriptionm-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1258596-39-2
-
Formula Weight579.52
-
Molecular FormulaC23H47BrO11
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCBr
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
-
Propargyl-PEG3-amine
Propargyl-PEG3-amine (Propargyl-PEG3-NH2) is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.
-
m-PEG7-4-nitrophenyl...
m-PEG7-4-nitrophenyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Amino-PEG11-amine
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.
